Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, May 30, 2024 | Back issues
Courthouse News Service Courthouse News Service

Allergan

Shareholders say in a federal class action that Allergan's stock dropped 41 percent in 15 months upon news that it could face criminal charges for colluding to fix the prices of generic pharmaceuticals.

NEWARK, N.J. – Allergan shareholders say in a federal class action that drugmaker’s stock dropped 41 percent, from $319.47 in 2015 to $188.82 last month, upon news that it could face criminal charges for colluding to fix the prices of generic pharmaceuticals.

Follow @bleonardcns
Categories / Business, Health, Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...